





Supplementary Figure 1: Forrest plots for pooled prevalence psoriasis of high risk of advanced liver fibrosis subgrouped based on (A) continent, (B) non-invasive tests, and (C) methotrexate user percentage






(C)


Supplementary Figure 2: Forrest plots for pooled prevalence psoriasis of low risk of advanced liver fibrosis subgrouped based on (A) continent, (B) non-invasive tests, and (C) methotrexate user percentage



(A)




(B)




(C)


Supplementary Figure 3: Forrest plots of pooled odds ratios for the association of variables with liver fibrosis; (A) age (B) male (C) PASI > 10 (D) Psoriatic arthritis (E) Cumulative MTX dose > 1500 mg (F) BMI>30 (G) DM (H) HT (I) DLP (J) Metabolic syndrome




(A)




(B)




(C)




(D)




(E)




(F)




(G)



(H)



(I)



(J)